Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28125365)

  • 1. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States.
    Wang J; Chmielowski B; Pellissier J; Xu R; Stevinson K; Liu FX
    J Manag Care Spec Pharm; 2017 Feb; 23(2):184-194. PubMed ID: 28125365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
    Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
    Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
    J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 8. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
    Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
    Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.
    Loong HH; Wong CKH; Leung LKS; Tan SC; Jen J; Lee MYK; Aguiar-Ibáñez R; Wang J
    Cost Eff Resour Alloc; 2020; 18():2. PubMed ID: 31969794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China.
    Tang WX; Shao RJ; Wang J; Scherrer E; Ma AX; Aguiar-Ibáñez R
    Value Health Reg Issues; 2022; 27():99-107. PubMed ID: 34922053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
    Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
    Pharmacoeconomics; 2017 Aug; 35(8):831-844. PubMed ID: 28620848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
    Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
    Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis.
    Barzey V; Atkins MB; Garrison LP; Asukai Y; Kotapati S; Penrod JR
    J Med Econ; 2013; 16(2):202-12. PubMed ID: 23057750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
    Wu B; Shi L
    JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
    Kohn CG; Zeichner SB; Chen Q; Montero AJ; Goldstein DA; Flowers CR
    J Clin Oncol; 2017 Apr; 35(11):1194-1202. PubMed ID: 28221865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.